← back to search

J. McKay

Wake Forest University · US
Area of research
Nephrology · Hepatology
Research interest
Research interests include Medicine, Tolerability, Adverse effect, Internal medicine, and Urology.
h-index
citations
25
works
1
NIH funding
primary concept
email

Recent publications

Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma
Blood 2023cited by 25position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Katja Weisel · National Institute Of Blood Disease and Bone Marrow Transplantation1 papers (2023–2023)Chetasi Talati · AbbVie (United States)1 papers (2023–2023)Cesar Rodriguez Valdes · Atrium Health Wake Forest Baptist1 papers (2023–2023)Ravi Vij · Columbia University1 papers (2023–2023)Shaji Kumar · Department of Internal Medicine1 papers (2023–2023)Anita D’Souza · Medical College of Wisconsin1 papers (2023–2023)Sascha A. Tuchman · University of North Carolina at Chapel Hill1 papers (2023–2023) · 1 papers (2023–2023)Shane Lee · Barwon Health1 papers (2023–2023)Tanya S Rosenberg · AbbVie (United States)1 papers (2023–2023)Jeremy A. Ross · AbbVie (United States)1 papers (2023–2023)Neha Korde · Weill Cornell Medicine1 papers (2023–2023)Rajvineeth Kumar Pothacamury · AbbVie (United States)1 papers (2023–2023)Peter M. Voorhees · Atrium Health Wake Forest Baptist1 papers (2023–2023)Orlando F. Bueno · AbbVie (United States)1 papers (2023–2023)Alfred Chung · University of California, San Francisco1 papers (2023–2023)Ziyi Jin · Jiangsu University1 papers (2023–2023)Akshanth R. Polepally · University of Minnesota, Twin Cities1 papers (2023–2023)Aarif Ahsan · New York University1 papers (2023–2023)Zhongling Feng · AbbVie (United States)1 papers (2023–2023)